Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe graves' orbitopathy: A randomized controlled study

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 2, 2015, Pages 422-431

  Salvi, Mario ^a   Vannucchi, Guia ^a   Currò, Nicola ^a   Campi, Irene ^a   Covelli, Danila ^a   Dazzi, Davide ^b   Simonetta, Simona ^a   Guastella, Claudio ^a   Pignataro, Lorenzo ^a   Avignone, Sabrina ^a   Beck Peccoz, Paolo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Ospedale di Fidenza   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; RITUXIMAB; GLUCOCORTICOID; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIPLOPIA; DISEASE ACTIVITY SCORE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPEPSIA; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOS; EYE MOVEMENT; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; HYPOTENSION; INJECTION SITE REACTION; INSOMNIA; MALE; MOOD DISORDER; NOSE DISEASE; ORBIT EDEMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; THROAT DISEASE; VISUAL DISORDER; COMPARATIVE STUDY; GRAVES OPHTHALMOPATHY; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; GRAVES OPHTHALMOPATHY; HUMANS; IMMUNOLOGIC FACTORS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; RITUXIMAB; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84922574945     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-3014     Document Type: Article

References (30)

1. Daumerie C. Epidemiology. In: Wiersinga WM, Kahaly G, eds. Graves' Orbitopathy: A Multidisciplinary Approach. 2nd ed. Basel, Switzerland: Karger; 2010: 33-38.
2. Bahn RS Graves' ophthalmopathy. N Engl J Med. 2010; 363: 726-738.
3. Smith TJ Pathogenesis of Graves' orbitopathy: a 2010 update. J Endocrinol Invest. 2010; 33: 414-421.
4. Bartalena L, Krassas GE, Wiersinga W, et al. European Group on Graves' Orbitopathy. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy. J Clin Endocrinol Metab.2012; 97: 4454-4463.
5. Vannucchi G, Covelli D, Campi I, et al. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor. Eur J Endocrinol. 2013; 170: 55-61.
6. Zang S, Ponto KA, Kahaly GJ. Clinical review: intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011: 320-332.
7. Salvi M, Vannucchi G, Campi I, et al. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol. 2006; 154: 511-517.
8. Salvi M, Vannucchi G, Campi I, et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol. 2007; 156: 33-40.
9. Salvi M, Vannucchi G, Beck-Peccoz P. Potential utility of rituximab in Graves' orbitopathy. J Clin Endocrinol Metab. 2013; 98: 4291-4299.
10. Mitchell AL, Gan EH, Morris M, et al. The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid refractory Graves' orbitopathy. Clin Endocrinol. (Oxf). 2013; 79: 437-442.
11. Mourits MP, Prummel MF, Wiersinga WM, Koorneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol. 1997; 47: 9-14.
12. Werner SC Classification of the eye changes of Graves' disease. J Clin Endocrinol Metab. 1969; 29(7): 982-984.
13. Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid. 2008; 18: 333-346.
14. Haggerty H, Richardson S, Mitchell K. Amodified method for measuring uniocular fields of fixation. Arch Ophthalmol. 2005; 123: 356-362.
15. Dickinson AJ, Perros P. Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol (Oxf). 2001; 55: 283-303.
16. Salvi M, Vannucchi G, Currò N, et al. Small dose of rituximab may be sufficient to treat Graves' orbitopathy: new insights into the mechanism of action. Arch Ophthalmol. 2012; 130: 122-124.
17. Terwee CB, Prummel MF, Gerding MN, Kahaly GJ, Dekker FW, Wiersinga WM. Measuring disease activity to predict therapeutic outcome in Graves' ophthalmopathy. Clin Endocrinol (Oxf). 2005; 62: 145-155.
18. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004; 350: 2572-2581.
19. Evens AM, Jovanovic BD, Su YC, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol. 2011; 22: 1170-1180.
20. van Vollenhoven RF, Emery P, Bingham CO 3rd, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013; 72: 1496-1502.
21. El Fassi D, Nielsen CH, Kjeldsen J, Clemmensen O, Hegedüs L. Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut. 2008; 57: 714-715.
22. Leo M, Marcocci C, Pinchera A, et al. Outcome of Graves' orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial. J Clin Endocrinol Metab. 2012; 97: E44-E48.
23. Descotes J. Immunotoxicity of monoclonal antibodies MAbs. 2009; 1: 104-111.
24. Eckstein AK, Plicht M, Lax H, et al. TSH-receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006; 91: 3464-3470.
25. El Fassi D, Banga JP, Gilbert JA, Padoa C, Hegedüs L, Nielsen CH. Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol. 2009; 130: 252-258.
26. Vannucchi G, Campi I, Bonomi M, et al. Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions, Clin Exp Immunol. 2010; 161: 436-443.
27. Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with graves' orbitopathy [publihsed online October 24, 2014]. J Clin Endocrinol Metab. doi: 10.1210/jc.2014-2572.
28. Ponto KA, Merkesdal S, Hommel G, Pitz S, Pfeiffer N, Kahaly GJ. Public health relevance of Graves' orbitopathy. J Clin Endocrinol Metab. 2013; 98: 145-152.
29. Estcourt S, Quinn AG, Vaidya B. Quality of life in thyroid eye disease: impact of quality of care. Eur J Endocrinol. 2011; 164: 649-655.
30. Wiersinga WM Quality of life in Graves' ophthalmopathy. Best Pract Res Clin Endocrinol Metab. 2012; 26: 359-370.